August 18, 2020 Atomic Spectroscopy Informatics & Software Life Science Tools

QIAGEN expands integrated coronavirus NGS and software solutions to accelerate COVID-19 research  

Hilden, Germany, and Germantown, Maryland, August 18, 2020 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) launched the innovative QIAseq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome, along with integrated analysis and interpretation workflows for insights into the evolution and spread of the virus that causes COVID-19 disease. The new... Read more

August 13, 2020 Lab Top-10 Liq. Handling & Robotics

QIAGEN to continue successful growth strategy focused on execution and greater value creation after voluntary public takeover offer falls short

Venlo, The Netherlands, August 13, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will continue to execute its successful growth strategy aiming to create significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific, Inc. (NYSE: TMO) did not achieve the minimum 66.67% acceptance threshold... Read more

July 22, 2020 Lab Top-10 Microscopy

QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher

Venlo, the Netherlands, July 22, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the publication of its Supplemental Reasoned Position Statement in response to the amended Offer Document published by Thermo Fisher Scientific Inc (NYSE: TMO) on July 17, 2020. The Offer Document relates to the recommended offer by Thermo Fisher... Read more

July 16, 2020 Lab Top-10 M&A, Partnerships PAI Top-10

Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement

WALTHAM, Mass. and VENLO, The Netherlands – July 16, 2020 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of Sample to Insight molecular diagnostics and sample preparation technologies, today announced that they have entered into an amendment... Read more

July 13, 2020 Lab Top-10 Liq. Handling & Robotics

QIAGEN provides update on Q2 2020 results, announces strong outlook for Q3 and FY 2020, and 2021 perspectives in light of coronavirus pandemic

Venlo, The Netherlands, July 13, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced additional information on preliminary results for the second quarter and first half of 2020, along with an outlook for continued strong growth trends in the third and fourth quarters of 2020. QIAGEN also provided initial perspectives that business trends are expected... Read more

July 9, 2020 Lab Top-10

QIAGEN announces preliminary results for Q2 2020

Venlo, The Netherlands, July 9, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces preliminary sales and adjusted earnings per share results for the second quarter of 2020.  Net sales rose approximately 18-19% at constant exchange rates (CER) from $381.6 million in the same period of 2019, and faster than the outlook for at least 12%... Read more

June 30, 2020 Lab Top-10 Microscopy

QIAGEN shareholders approve all agenda items related to acquisition by Thermo Fisher Scientific at Annual General Meeting

Venlo, the Netherlands, June 30, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that its shareholders today approved all agenda items at the Company’s Annual General Meeting related to the proposed voluntary public takeover offer for the acquisition of all ordinary shares in QIAGEN by Quebec B.V., a wholly-owned subsidiary of Thermo... Read more

June 23, 2020 Atomic Spectroscopy PR/Corporate

QIAGEN provides information on potential capital gain from its minority investment in ArcherDX

Venlo, the Netherlands, June 23, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that according to the intended business combination between Invitae (NYSE: NVTA) and ArcherDX, QIAGEN could realize a significant pre-tax capital gain from its minority investment in ArcherDX, a U.S.-based genomics analysis company involved in precision oncology. As of June... Read more

June 22, 2020 Lab Top-10

QIAGEN announces plans to release preliminary Q2 2020 results

Venlo, the Netherlands, June 22, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it plans to provide in the first half of July 2020 an overview of preliminary results for the second quarter and first half of 2020, along with perspectives on anticipated business trends for the third quarter of... Read more

May 6, 2020 PR/Corporate

QIAGEN reports full results for first quarter of 2020

Q1 2020 results: Net sales of $372.1 million (+7% actual, +9% CER vs. ~+2-3% CER outlook) Diluted EPS $0.17; adjusted EPS $0.34 ($0.34 CER vs. ~$0.28-0.29 CER outlook) Fully mobilized teams addressing COVID-19 pandemic testing demand, dramatically ramping up production of RNA extraction kits, QIAstat-Dx tests and components for third-party tests QIAGEN expects higher results... Read more